10X Genomics Inc TXG Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 21, 2024 (filed on Mar 25, 2024)

Insider Name:

Saxonov Serge

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

88,854

Price:

--
Mar 21, 2024 (filed on Mar 25, 2024)

Insider Name:

Hindson Benjamin J.

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

71,083

Price:

--
Mar 21, 2024 (filed on Mar 25, 2024)

Insider Name:

McAnear Justin J.

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

53,312

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Saxonov Serge

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

-1,086

Price:

--
Mar 04, 2024 (filed on Mar 06, 2024)

Insider Name:

Saxonov Serge

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,660

Price:

$44.00
Feb 22, 2024 (filed on Feb 26, 2024)

Insider Name:

Saxonov Serge

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,821

Price:

$46.34
Feb 22, 2024 (filed on Feb 26, 2024)

Insider Name:

Hindson Benjamin J.

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,613

Price:

$46.34
Feb 22, 2024 (filed on Feb 26, 2024)

Insider Name:

McAnear Justin J.

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,865

Price:

$46.34
Feb 15, 2024 (filed on Feb 20, 2024)

Insider Name:

Saxonov Serge

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,700

Price:

$49.43
Feb 15, 2024 (filed on Feb 20, 2024)

Insider Name:

Saxonov Serge

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,300

Price:

$48.58

Filings by filing date

Mar 21, 2024 (filed on Mar 25, 2024)

Insider Name:

Saxonov Serge

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

88,854

Price:

--
Mar 21, 2024 (filed on Mar 25, 2024)

Insider Name:

Hindson Benjamin J.

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

71,083

Price:

--
Mar 21, 2024 (filed on Mar 25, 2024)

Insider Name:

McAnear Justin J.

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

53,312

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Saxonov Serge

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

-1,086

Price:

--
Mar 04, 2024 (filed on Mar 06, 2024)

Insider Name:

Saxonov Serge

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,660

Price:

$44.00
Feb 22, 2024 (filed on Feb 26, 2024)

Insider Name:

Saxonov Serge

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,821

Price:

$46.34
Feb 22, 2024 (filed on Feb 26, 2024)

Insider Name:

Hindson Benjamin J.

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,613

Price:

$46.34
Feb 22, 2024 (filed on Feb 26, 2024)

Insider Name:

McAnear Justin J.

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,865

Price:

$46.34
Feb 15, 2024 (filed on Feb 20, 2024)

Insider Name:

Saxonov Serge

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,700

Price:

$49.43
Feb 15, 2024 (filed on Feb 20, 2024)

Insider Name:

Saxonov Serge

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,300

Price:

$48.58

News

Biz Brief

Sector: Healthcare	Industry: Medical Equipment, Supplies & Distribution

See Regulatory Filings on SEC

Company Contact

Address:	6230 Stoneridge Mall Road PLEASANTON CA 94588
Tel:	N/A
Website:	https://www.10xgenomics.com
IR:	See website

Key People

Benjamin J. Hindson President, Co-Founder, Chief Scientific Officer, Director	Serge Wilson Saxonov Chief Executive Officer, Co-Founder, Director	Justin J. Mcanear Chief Financial Officer
Eric S. Whitaker Chief Legal Officer

Business Overview

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

Financial Overview

For the fiscal year ended 31 December 2023, 10X Genomics Inc revenues increased 20% to $618.7M. Net loss increased 54% to $255.1M. Revenues reflect Instruments segment increase of 71% to $123.5M, Consumables segment increase of 10% to $479.6M, United States segment increase of 26% to $360.1M, Europe, the Middle East and Africa segment increase of 22% to $142.3M.

Employees:	1,259 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$2,924M as of Dec 31, 2023
Annual revenue (TTM):	$618.73M as of Dec 31, 2023
EBITDA (TTM):	-$227.02M as of Dec 31, 2023
Net annual income (TTM):	-$255.10M as of Dec 31, 2023
Free cash flow (TTM):	-$64.72M as of Dec 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	119,166,544 as of Jan 31, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization